安杰思净利2.93亿分红及回购占48% 推进全球化国际市场销售收入增36%

Core Viewpoint - Anjiesi (688581.SH) is rapidly advancing its global layout in the field of digestive endoscopy intervention, leading to continuous growth in profitability [1][2] Financial Performance - In 2024, the company achieved operating revenue of 637 million yuan, a year-on-year increase of 25.14% [1][2] - The net profit attributable to shareholders was 293 million yuan, up 35.06% year-on-year [1][2] - The net profit excluding non-recurring gains and losses was 273 million yuan, reflecting a year-on-year growth of 28.62% [1][2] - The company has maintained positive growth in operating performance for four consecutive years [2] International Market Expansion - In 2024, Anjiesi's international market sales revenue reached 333 million yuan, a year-on-year increase of 36.19% [1][2] - The domestic market sales revenue was approximately 300 million yuan, increasing by 14.63% year-on-year [2] - The company has established effective cooperation channels with nearly 600 hospitals and covered over 2400 terminal hospitals [3] Production and Investment - Anjiesi is advancing its production base in Thailand, with the first phase expected to be operational by the second quarter of 2025, involving an investment of 180 million yuan [3] - The company plans to further invest in the Thai market, including the construction of a second-phase production base [3] Employee Incentives - Anjiesi has implemented a restricted stock incentive plan for 2025, granting 16,100 shares at a price of 46.16 yuan per share, accounting for 0.02% of the total share capital [4][5] - The company has set performance assessment targets for 2025 and 2026, requiring specific revenue and net profit thresholds for the stock incentive to fully vest [5] Research and Development - In 2024, Anjiesi's R&D expenses amounted to 59.21 million yuan, a year-on-year increase of 43.53%, representing 9.30% of operating revenue [5][6] - The company has applied for a total of 367 patents, with 100 patents granted, and over 48% of these patents have been applied to related products [6] Shareholder Returns - Anjiesi plans to distribute a cash dividend of 13.8 yuan per 10 shares, totaling 111 million yuan for 2024 [6] - The total amount for cash dividends and share buybacks in 2024 is projected to be 142 million yuan, accounting for 48.46% of the company's net profit [6]